When In Manila And The Long Game Of Building A Lasting Brand

A platform built on consistency now faces reinvention, as When In Manila shifts from founder-led identity to a shared space shaped by its growing community.

Unilever Champions Women Within The Workplace And Beyond Through Purposeful Programs And Partnerships

Unilever Philippines highlights how intentional policies and programs can empower women to lead, grow, and thrive across workplaces and communities.

Vivant Posts Double Digit Growth In 2025, Core Net Income Surges 21% To Php 2.7 Billion On Solid Power Generation Results

Vivant Corporation posts strong earnings growth, reflecting steady performance across its energy and water businesses amid shifting industry dynamics.

Reaching The Philippines’ Last Mile: Private Sector Innovation To Bridge The Financial Inclusion Gap

Private sector innovation is stepping in to bridge the gap between access and actual financial inclusion in underserved communities.

Oxford University Vaccine Trials To Resume

Trials of a coronavirus vaccine being developed by Oxford University and British drug manufacturer AstraZeneca will resume after being paused.

Oxford University Vaccine Trials To Resume

87
87

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Trials of a coronavirus vaccine being developed by Oxford University and British drug manufacturer AstraZeneca will resume after being paused, they said in a statement on Saturday.

The trials had been paused last week after a participant fell ill.

According to the vaccine partners, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) said trials could resume, after a committee of theirs inspected safety data.

Oxford University said in a statement: “Globally some 18,000 individuals have received study vaccines as part of the trial. In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”

AstraZeneca said in a statement: “The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.” (PNA)